Caricamento...
Dual Fulvestrant‐Trametinib Therapy in Recurrent Low‐Grade Serous Ovarian Cancer
Low‐grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK‐inhibitors displays synergism in preclinical ovarian cancer models, however....
Salvato in:
| Pubblicato in: | Oncologist |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356701/ https://ncbi.nlm.nih.gov/pubmed/32369640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0101 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|